New Insights into the Rational Use of HCV+ Organs Worldwide.

Clicks: 313
ID: 63389
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 9 articles by views in clinical transplantation

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Hepatitis C (HCV) is a worldwide health problem. Effective therapies for HCV infection, coupled with an increase in deceased donors due to the opioid epidemic has led to broader availability and use of HCV infected donor organs, including HCV nucleic acid test positive (NAT+) donors in HCV negative recipients. In this review we discuss the prevalence of HCV infection, trends in the use of HCV infected donors and outcomes for those who receive HCV seropositive or HCV NAT+ donor organs. We discuss management considerations such as Hepatitis B reactivation, selection of the optimal direct acting antiviral regimen and potential complications. We also present a framework for the rational use of HCV infected donor organs in the future.
Reference Key
morales2019newclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Morales, Jose;Sawinski, Deirdre;
Journal clinical transplantation
Year 2019
DOI
10.1111/ctr.13739
URL
Keywords
hepatitis c kidney transplant liver transplant heart transplant lung transplant

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.